Featured Research

from universities, journals, and other organizations

Heart Risks From Vioxx Happen Much Earlier Than Believed

Date:
May 4, 2006
Source:
Queen's University
Summary:
A new study led by Queen's University researcher Linda Lévesque shows that heart attacks related to the use of Vioxx -- a drug once popular for the treatment of pain and inflammation -- can occur within the first two weeks of use.

A new study led by Queen's University researcher Linda Lévesque shows that heart attacks related to the use of Vioxx -- a drug once popular for the treatment of pain and inflammation -- can occur within the first two weeks of use.

A quarter of patients who suffered a heart attack while taking Vioxx did so within the first two weeks of their first Vioxx prescription, says Prof. Lévesque , of Queen's Department of Community Health and Epidemiology. "This demonstrates that cardiovascular risks from taking Vioxx may occur much earlier than previously believed."

Conducted with McGill University researchers James Brophy and Bin Zhang, the findings will be published on-line May 2 in the Canadian Medical Association Journal.

"Our previous study on COX-2 inhibitors, which included Vioxx and Celebrex, evaluated whether there was an increased risk of heart attack while taking these medications; the answer was yes for Vioxx," explains Prof. Lévesque. In the current study, funded by the Canadian Institutes for Health Research (CIHR), the pattern of cardiovascular risk in Québec seniors was assessed over a three-year period.

The additional cardiovascular risk actually decreased with longer duration of use, suggesting that the period of highest susceptibility for most people taking Vioxx may occur earlier than previously believed. The study also documents that cardiovascular risk returns to normal within one month of stopping the drug.

Vioxx was voluntarily withdrawn from the market on September 30, 2004 after a study showed that it doubled patients' risk of heart attacks and strokes after 18 months of use. This study is the first to specifically address the question of the timing of cardiovascular risk associated with COX-2 inhibitors.


Story Source:

The above story is based on materials provided by Queen's University. Note: Materials may be edited for content and length.


Cite This Page:

Queen's University. "Heart Risks From Vioxx Happen Much Earlier Than Believed." ScienceDaily. ScienceDaily, 4 May 2006. <www.sciencedaily.com/releases/2006/05/060504081246.htm>.
Queen's University. (2006, May 4). Heart Risks From Vioxx Happen Much Earlier Than Believed. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2006/05/060504081246.htm
Queen's University. "Heart Risks From Vioxx Happen Much Earlier Than Believed." ScienceDaily. www.sciencedaily.com/releases/2006/05/060504081246.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins